Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Total Liabilities: 2020-2024

Historic Total Liabilities for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $38.7 million.

  • Janux Therapeutics' Total Liabilities rose 23.89% to $48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.2 million, marking a year-over-year increase of 23.89%. This contributed to the annual value of $38.7 million for FY2024, which is 7.42% up from last year.
  • Per Janux Therapeutics' latest filing, its Total Liabilities stood at $38.7 million for FY2024, which was up 7.42% from $36.1 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Total Liabilities registered a high of $43.3 million during FY2022, and its lowest value of $9.2 million during FY2020.
  • Its 3-year average for Total Liabilities is $39.4 million, with a median of $38.7 million in 2024.
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 220.59% in 2022, then fell by 16.67% in 2023.
  • Over the past 5 years, Janux Therapeutics' Total Liabilities (Yearly) stood at $9.2 million in 2020, then spiked by 46.21% to $13.5 million in 2021, then surged by 220.59% to $43.3 million in 2022, then declined by 16.67% to $36.1 million in 2023, then grew by 7.42% to $38.7 million in 2024.